Cargando…
Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack
INTRODUCTION: The risk of disability and mortality is high among recurrent stroke, which highlights the importance of secondary prevention measures. We aim to evaluate medication persistence for secondary prevention and the prognosis of acute ischaemic stroke or transient ischaemic attack (TIA) in C...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485245/ https://www.ncbi.nlm.nih.gov/pubmed/33526631 http://dx.doi.org/10.1136/svn-2020-000471 |
_version_ | 1784577494581510144 |
---|---|
author | Zhang, Lei Shi, Junfeng Pan, Yuesong Li, Zixiao Yan, Hongyi Liu, Chelsea Lv, Wei Meng, Xia Wang, Yongjun |
author_facet | Zhang, Lei Shi, Junfeng Pan, Yuesong Li, Zixiao Yan, Hongyi Liu, Chelsea Lv, Wei Meng, Xia Wang, Yongjun |
author_sort | Zhang, Lei |
collection | PubMed |
description | INTRODUCTION: The risk of disability and mortality is high among recurrent stroke, which highlights the importance of secondary prevention measures. We aim to evaluate medication persistence for secondary prevention and the prognosis of acute ischaemic stroke or transient ischaemic attack (TIA) in China. METHODS: Patients with acute ischaemic stroke or TIA from the China National Stroke Registry II were divided into 3 groups based on the percentage of persistence in secondary prevention medication classes from discharge to 3 months after onset (level I: persistence=0%, level II: 0%<persistence<100%, level III: persistence=100%). The primary outcome was recurrent stroke. The secondary outcomes included composite events (stroke, myocardial infarction or death from cardiovascular cause), all-cause death and disability (modified Rankin Scale score=3–5) from 3 months to 1 year after onset. Recurrent stroke, composite events and all-cause death were performed using Cox regression model, and disability was identified through logistic regression model using the generalised estimating equation method. RESULTS: 18 344 patients with acute ischaemic stroke or TIA were included, 315 (1.7%) of whom experienced recurrent strokes. Compared with level I, the adjusted HR of recurrent stroke for level II was 0.41 (95% CI 0.31 to 0.54) and level III 0.37 (0.28 to 0.48); composite events for level II 0.41 (0.32 to 0.53) and level III 0.38 (0.30 to 0.49); all-cause death for level II 0.28 (0.23 to 0.35) and level III 0.20 (0.16–0.24). Compared with level I, the adjusted OR of disability for level II was 0.89 (0.77 to 1.03) and level III 0.82 (0.72 to 0.93). CONCLUSIONS: Persistence in secondary prevention medications, especially in all classes of medications prescribed by the physician, was associated with lower hazard of recurrent stroke, composite events, all-cause death and lower odds of disability in patients with acute ischaemic stroke or TIA. |
format | Online Article Text |
id | pubmed-8485245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84852452021-10-08 Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack Zhang, Lei Shi, Junfeng Pan, Yuesong Li, Zixiao Yan, Hongyi Liu, Chelsea Lv, Wei Meng, Xia Wang, Yongjun Stroke Vasc Neurol Original Research INTRODUCTION: The risk of disability and mortality is high among recurrent stroke, which highlights the importance of secondary prevention measures. We aim to evaluate medication persistence for secondary prevention and the prognosis of acute ischaemic stroke or transient ischaemic attack (TIA) in China. METHODS: Patients with acute ischaemic stroke or TIA from the China National Stroke Registry II were divided into 3 groups based on the percentage of persistence in secondary prevention medication classes from discharge to 3 months after onset (level I: persistence=0%, level II: 0%<persistence<100%, level III: persistence=100%). The primary outcome was recurrent stroke. The secondary outcomes included composite events (stroke, myocardial infarction or death from cardiovascular cause), all-cause death and disability (modified Rankin Scale score=3–5) from 3 months to 1 year after onset. Recurrent stroke, composite events and all-cause death were performed using Cox regression model, and disability was identified through logistic regression model using the generalised estimating equation method. RESULTS: 18 344 patients with acute ischaemic stroke or TIA were included, 315 (1.7%) of whom experienced recurrent strokes. Compared with level I, the adjusted HR of recurrent stroke for level II was 0.41 (95% CI 0.31 to 0.54) and level III 0.37 (0.28 to 0.48); composite events for level II 0.41 (0.32 to 0.53) and level III 0.38 (0.30 to 0.49); all-cause death for level II 0.28 (0.23 to 0.35) and level III 0.20 (0.16–0.24). Compared with level I, the adjusted OR of disability for level II was 0.89 (0.77 to 1.03) and level III 0.82 (0.72 to 0.93). CONCLUSIONS: Persistence in secondary prevention medications, especially in all classes of medications prescribed by the physician, was associated with lower hazard of recurrent stroke, composite events, all-cause death and lower odds of disability in patients with acute ischaemic stroke or TIA. BMJ Publishing Group 2021-02-01 /pmc/articles/PMC8485245/ /pubmed/33526631 http://dx.doi.org/10.1136/svn-2020-000471 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Zhang, Lei Shi, Junfeng Pan, Yuesong Li, Zixiao Yan, Hongyi Liu, Chelsea Lv, Wei Meng, Xia Wang, Yongjun Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
title | Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
title_full | Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
title_fullStr | Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
title_full_unstemmed | Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
title_short | Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
title_sort | secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485245/ https://www.ncbi.nlm.nih.gov/pubmed/33526631 http://dx.doi.org/10.1136/svn-2020-000471 |
work_keys_str_mv | AT zhanglei secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT shijunfeng secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT panyuesong secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT lizixiao secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT yanhongyi secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT liuchelsea secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT lvwei secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT mengxia secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack AT wangyongjun secondarypreventionmedicationpersistenceandprognosisofacuteischaemicstrokeortransientischaemicattack |